Welcome to our dedicated page for Cellebrite Di news (Ticker: CLBTW), a resource for investors and traders seeking the latest updates and insights on Cellebrite Di stock.
Cellebrite Di Ltd (NASDAQ: CLBTW) delivers critical Digital Intelligence solutions for modern investigative challenges. This news hub provides stakeholders with essential updates about the company’s technological advancements, regulatory compliance, and market positioning.
Access consolidated information on product launches, partnership announcements, and financial disclosures relevant to CLBTW’s role in digital forensics and corporate investigations. Our curated collection serves investors and professionals needing to monitor developments in SaaS-based investigative tools, eDiscovery innovations, and cybersecurity capabilities.
Key updates include earnings reports, leadership changes, and technology patents across Cellebrite’s Case-to-Closure platform. All content undergoes strict verification to ensure accuracy and relevance for decision-makers in both public sector and corporate environments.
Bookmark this page for streamlined access to CLBTW’s latest developments in legally compliant data analysis solutions. Regularly updated to reflect the company’s progress in addressing evolving digital security demands.
Cellebrite, a leader in digital investigative solutions, announced the availability of its Endpoint Inspector SaaS on the AWS Marketplace. This solution, part of Cellebrite's Case-to-Closure platform, allows corporate investigators and eDiscovery practitioners to collect and analyze data in real-time from various remote devices. Utilizing AWS cloud infrastructure, Endpoint Inspector SaaS enhances data extraction speed and insight depth for corporate investigations, such as fraud and intellectual property theft. It supports hybrid work environments, enabling secure, consent-based data collection without the need for physical device access. AWS Marketplace facilitates easy deployment, automated billing, and payment tracking.
Cellebrite (NASDAQ: CLBT) announced its Q1 2024 results, reporting a 27% year-over-year increase in Annual Recurring Revenue (ARR) to $331.8 million. Q1 2024 revenue rose by 26% to $89.6 million, driven by a 29% growth in subscription revenue. The company recorded a GAAP net loss of $71.4 million and a non-GAAP net income of $16.9 million. Adjusted EBITDA stood at $17.6 million with a 19.7% margin. CEO Yossi Carmil emphasized the global expansion and profitability improvements, noting the positive reception of new products like the Inseyets digital forensics software. The company reaffirmed its outlook for 2024, expecting ARR between $380 million and $400 million, and revenue between $370 million and $380 million for the full year.
Cellebrite (NASDAQ: CLBT), a global leader in digital investigative solutions, announced its participation in several investor conferences from May 26 to June 5, 2024. The company will engage in various formats, including fireside chats, 1x1 meetings, and presentations.
Key dates include May 26 at the Oppenheimer 25th Annual Israeli Conference, May 29 at the Craig-Hallum Institutional Investor Conference, May 30 at the TD Cowen 52nd Annual Technology, Media & Telecom Conference, and June 5 at the William Blair 44th Annual Growth Stock Conference.
Cellebrite executives like Dana Gerner (CFO), Andrew Kramer (VP), and Yossi Carmil (CEO) will present at these events. The conferences are opportunities for the company to highlight its digital investigative solutions and connect with investors.
FAQ
What is the current stock price of Cellebrite Di (CLBTW)?
